Phenylephrine IV Composition in Polymer Bags for Low-Concentration Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phenylephrine hydrochloride formulations require dilution before use, are prone to microbial contamination, and have stability issues, especially at low concentrations, with potential side effects from preservatives like metabisulfite.
Innovation Solution
Development of ready-to-administer, antioxidant-free phenylephrine compositions at low concentrations (0.04-0.4 mg/ml) with a pH of 4.5-5.5, using acetate buffer and optional metal ion chelators, packaged in flexible polymer bags with oxygen scavengers, ensuring stability and sterility for up to six months at ambient temperatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If phenylephrine hydrochloride is formulated as a concentrate requiring dilution, then storage stability is improved, but ease of operation deteriorates due to required dilution steps and risk of contamination
Solution Approach 1:
The patent prepares phenylephrine hydrochloride at the final ready-to-administer concentration (0.04-0.4 mg/ml) directly during manufacturing, eliminating the need for post-manufacturing dilution. This preliminary action ensures the solution is immediately usable while maintaining stability through optimized formulation including acetate buffer and controlled pH (4.5-5.5).
Solution Approach 2:
The patent optimizes multiple parameters simultaneously: pH (4.5-5.5), buffer composition (acetate buffer), metal ion chelation (EDTA), and packaging (flexible polymer bags with oxygen scavengers). These parameter changes collectively enable ready-to-administer low concentration formulations to maintain stability without requiring dilution or preservatives.
2Reliability
If preservatives like metabisulfite are added to prevent microbial contamination, then reliability is improved, but object-affected harmful factors worsen due to potential side effects
Solution Approach 1:
The patent removes traditional preservatives like metabisulfite from the formulation entirely. Instead, it relies on optimized pH control (4.5-5.5 using acetate buffer), metal ion chelation with EDTA, and hermetic packaging with oxygen scavengers to prevent microbial growth, thereby eliminating preservative-related side effects while maintaining sterility.
Solution Approach 2:
The patent introduces EDTA as a metal ion chelator that acts as an intermediary to bind metal ions that could catalyze degradation reactions. This alternative approach to stabilization avoids the use of harmful preservatives while maintaining formulation integrity and preventing microbial contamination through multiple complementary mechanisms.
3Ease of operation
If phenylephrine is stored at low concentrations, then ease of operation is improved by eliminating dilution steps, but stability deteriorates with increased degradation
Solution Approach 1:
The patent optimizes multiple parameters to stabilize low concentration phenylephrine (0.04-0.4 mg/ml): pH control (4.5-5.5), acetate buffer system, EDTA metal ion chelation, and oxygen scavenger packaging. These parameter changes collectively prevent degradation even at ready-to-administer concentrations without requiring dilution from concentrates.
Solution Approach 2:
The patent creates a composite formulation system combining phenylephrine hydrochloride with acetate buffer, EDTA, and oxygen scavengers in flexible polymer packaging. This composite approach provides synergistic protection against degradation mechanisms, enabling low concentration formulations to remain stable for extended periods without preservatives or concentration adjustment.
4Object-affected harmful factors
If antioxidant-free formulations are used, then object-affected harmful factors are reduced by eliminating preservative side effects, but stability worsens due to increased oxidation risk
Solution Approach 1:
The patent uses EDTA as a metal ion chelating intermediary that binds transition metals which would otherwise catalyze oxidative degradation of phenylephrine. This alternative stabilization mechanism provides oxidation protection without requiring traditional antioxidants or preservatives, eliminating their associated side effects while maintaining formulation stability.
Solution Approach 2:
The patent employs flexible polymer bags containing oxygen scavengers that actively remove oxygen from the headspace and solution environment. This creates an inert, low-oxygen atmosphere that prevents oxidative degradation of phenylephrine without requiring antioxidant additives, thereby maintaining stability while avoiding preservative-related harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain minimal degradation (<0.5%) and eliminate the need for dilution, reducing contamination risks and extending shelf life while maintaining therapeutic efficacy.
Implementation Method 1
using acetate buffer and optional metal ion chelators, packaged in flexible polymer bags with oxygen scavengers, ensuring stability and sterility for up to six months at ambient temperatures
Implementation Method 2
packaged in flexible polymer bags with oxygen scavengers, ensuring stability and sterility for up to six months at ambient temperatures
Implementation Method 3
using acetate buffer and optional metal ion chelators, packaged in flexible polymer bags with oxygen scavengers
Data Source
AI summary
A ready-to-administer antioxidant free phenylephrine compositions has improved stability and is optionally free of metal chelating agents. Contemplated compositions are preferably packaged into a flexible polymer bag and maintain degradation of the phenylephrine at remarkably low levels, even over extended storage periods.